{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423790,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.282252","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T03:23:49Z","timestamp":1674098629000},"page":"2218-2223","source":"Crossref","is-referenced-by-count":10,"title":["Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis"],"prefix":"10.3324","volume":"108","author":[{"given":"Mengyang","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin K.","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarsheen","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"50753","doi-asserted-by":"crossref","unstructured":"Tam CS, Opat S, Simpson D. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021; 5(12):2577-2585.","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"50754","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. Three-year follow-Up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023; 41(3):555-567.","DOI":"10.1200\/JCO.21.02370"},{"key":"50755","doi-asserted-by":"crossref","unstructured":"Wang M, Rule S, Zinzani PL. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018; 391(10121):659-667.","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"50756","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"50757","doi-asserted-by":"crossref","unstructured":"Di M, Cui C, Kothari SK. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Adv. 2022; 6(11):3339-3342.","DOI":"10.1182\/bloodadvances.2021006934"},{"key":"50758","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012; 367(6):520-531.","DOI":"10.1056\/NEJMoa1200920"},{"key":"50759","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol. 2020; 38(3):248-256.","DOI":"10.1200\/JCO.19.01294"},{"key":"50760","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl B. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up Study. J Clin Oncol. 2019; 37(12):984-991.","DOI":"10.1200\/JCO.18.00605"},{"key":"50761","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphoma. 2022. Publisher Full Text|"},{"key":"50762","doi-asserted-by":"crossref","unstructured":"Martin P, Cohen JB, Wang M. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol. 2023; 41(3):541-554.","DOI":"10.1200\/JCO.21.02698"},{"key":"50763","doi-asserted-by":"crossref","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018; 73(7):980-987.","DOI":"10.1093\/gerona\/glx229"},{"key":"50764","doi-asserted-by":"crossref","unstructured":"van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-633.","DOI":"10.1097\/MLR.0b013e31819432e5"},{"key":"50765","doi-asserted-by":"crossref","unstructured":"Hill BT, Switchenko JM, Martin P. Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine+ rituximab without autologous transplant. Blood. 2019; 134(Suppl 1):S1525.","DOI":"10.1182\/blood-2019-129404"},{"key":"50766","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Knauf W, Goerner M. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016; 34(Suppl 15):S7503.","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"50767","doi-asserted-by":"crossref","unstructured":"Bega G, Olivieri J, Riva M. Rituximab and bendamustine (BR) compared with rituximab, bendamustine, and cytarabine (R-BAC) in previously untreated elderly patients with mantle cell lymphoma. Cancers (Basel). 2021; 13(23):6089.","DOI":"10.3390\/cancers13236089"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282252\/75215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282252\/75896","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10942\/75215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:12Z","timestamp":1794045792000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282252","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}